Adastra Pharmaceuticals Announces that Data from Phase 1b Clinical Trial of Zotiraciclib Will Be Presented at ASCO 2019

Thursday, May 16, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) for the Treatment of Recurrent Malignant Gliomas

Title:

Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults

Session:

Central Nervous System Tumors

Abstract Number:

2031

Date:

June 2, 2019

Time:

8:00 AM – 11:00 AM, CDT

Location:

McCormick Place, Chicago, IL



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store